PeptideInfo
العربيةGet the app
☰
Neurological & CognitiveNot approved (US)

DSIP

Delta Sleep-Inducing Peptide

Proposed actions involve thalamic and hypothalamic control of delta-wave sleep, sigma receptors and opioid signaling. Reduced ACTH and LH secretion and inhibition of lipid peroxidation may contribute to its hormonal and antioxidant effects.

Not medical advice. Educational reference only.

Typical dose
25–100 mcg injectable in research; no established human dose
Route
Intranasal; injectable
Storage
Keep refrigerated at 2–8 °C and use within 28 days.

What is DSIP?

Delta sleep-inducing peptide, or DSIP, contains nine amino acids. Monnier and colleagues first isolated it in 1977 from thalamic perfusate collected from sleeping rabbits; infusion produced slow-wave delta sleep. Later investigations examined pain signaling, stress responses, body-temperature regulation and antioxidant activity. Clinical findings are sparse and inconsistent, and its mechanism is still poorly understood. DSIP remains restricted to research use.

Mechanism of action

Proposed actions involve thalamic and hypothalamic control of delta-wave sleep, sigma receptors and opioid signaling. Reduced ACTH and LH secretion and inhibition of lipid peroxidation may contribute to its hormonal and antioxidant effects.

Targets: Sigma receptors · Hypothalamic-pituitary axis · Thalamic sleep centers

Research indications

  • Cognitive Function

    Effective

    Potential cognitive benefits include better memory, concentration and information processing.

  • Neuroprotection

    Moderate

    Neurons may gain protection against oxidative injury and inflammation.

  • Mood & Anxiety

    Moderate

    Some studies suggest reduced anxiety and more stable mood.

Interactions

  • Stimulants (Modafinil, Adderall)

    Caution

  • MAOIs / SSRIs

    Monitor

  • Racetams

    Caution

  • NAD+

    Compatible

  • BPC-157

    Compatible

How to reconstitute and inject

Diluent: Use bacteriostatic water only. Avoid saline because it can cause precipitation.

  1. Take the DSIP vial out of refrigeration and wait 15–20 minutes for it to reach room temperature.
  2. Disinfect the rubber stopper with an alcohol swab, then let it dry fully in the air.
  3. Use a sterile syringe to measure the calculated amount of bacteriostatic water. Use BAC water only; avoid saline because precipitation can occur.
  4. Direct the water slowly onto the inner vial wall rather than onto the powder.
  5. Rotate the vial gently to mix. Never shake it vigorously; this can degrade the peptide.
  6. Wait 2–3 minutes for complete dissolution, and check that the liquid is transparent and colorless.
  7. Measure your calculated dose into an insulin syringe for a subcutaneous injection.
  8. Choose the abdomen, thigh or upper arm for injection. Change the site each time to help prevent lipodystrophy.
  9. Refrigerate the mixed vial at 2–8 °C and use it within 28 days.

What to expect

Week 1–2
Small improvements in mood and concentration may start, and sleep often improves early.
Week 2–4
Anecdotal human reports mention clearer thinking, easier word recall and less brain fog.
Week 4–8
Cognitive changes may become consistent, with better working memory and responses to stress.
Week 8+
Cognitive and neurological benefits may continue and can persist after a cycle ends.

Side effects and safety

  • Headaches, especially when beginning use
  • Mild restlessness or anxiety with some compounds
  • Irritation of the nose with intranasal use
  • Disrupted sleep when administration is too near bedtime
  • Changes in mood or emotional stability · Rare

DSIP: not approved in the US.

Regulatory status

  • US

    Not approved

    FDA — no approval; research use only. No 503A ban is recorded; affirmative compounding authorization remains unestablished.

    Rx required
    No
    Telehealth
    N/A

Frequently asked questions

What is DSIP?

Delta sleep-inducing peptide, or DSIP, contains nine amino acids. Monnier and colleagues first isolated it in 1977 from thalamic perfusate collected from sleeping rabbits; infusion produced slow-wave delta sleep. Later investigations examined pain signaling, stress responses, body-temperature regulation and antioxidant activity. Clinical findings are sparse and inconsistent, and its mechanism is still poorly understood. DSIP remains restricted to research use.

How are research schedules specified?

Starting schedules use a low dose and standard schedules use a standard amount, once daily by an intranasal or injectable route. Neither schedule gives a numeric dose. These labels do not establish a human regimen or an amount suitable for calculation.

What additional dosing or pharmacokinetic information is available?

Research discussions include injectable doses of 25–100 mcg and an approximate half-life of 30 minutes. No established human dose exists. Consult a qualified healthcare professional and current literature when interpreting these experimental figures.

What safety considerations matter?

Adverse effects depend on the amount used, the route and individual response. Human adverse-effect profiles remain incompletely characterized. Consult your healthcare provider before combining compounds, and report unexpected symptoms. The timelines and compatibility categories do not establish clinical effectiveness or prove that combinations are safe.

References

  1. Delta sleep-inducing peptide (DSIP): A review (1986)

  2. DSIP and stress tolerance in rats (1988)

  3. Delta sleep-inducing peptide. (2001)

    PMID 11437870DOI 10.1046/j.1365-2346.2001.00917.x

  4. Delta-sleep-inducing peptide (DSIP): a review. (1984)

    PMID 6145137DOI 10.1016/0149-7634(84)90022-8

  5. DSIP studies on ClinicalTrials.gov (2024)